



Q2, 2014-15 Results, Turnover up by 20% to Rs. 242.9 crores Highest Quarterly Turnover Recorded

Mumbai, November 5th **2014**: Hikal Ltd, a preferred long-term partner for leading global life sciences companies, announced its unaudited results for the period ending 30th September 2014.

Performance highlights for the 3 months ended 30th September 2014

- Net sales up by 20% to Rs. 242.9 crores as compared to Rs. 202.8 crores in the corresponding period of the previous year.
- Pharmaceutical sales up by 4% to Rs. 140. 4 crores as compared to Rs. 134.7 crores in the corresponding period of the previous year.
- Crop protection sales up by 51% to Rs. 102.5 crores as compared to Rs. 68.1 crores in the corresponding period of the previous year.
- EBIDTA was lower by 8.4% to Rs. 53.9 crores as compared to Rs. 58.9 crores in the corresponding period of the previous year.
- Net Profit was up by 8% at Rs. 15.2 crores as compared to Rs. 14.1 crores in the corresponding period of the previous year.

Performance highlights for the 6 months ended 30th September 2014

- Net sales up by 12.5% to Rs. 433.3 crores as compared to Rs. 385.3 crores in the corresponding period of the previous year.
- Pharmaceutical sales up by 3.2% to Rs. 261.6 crores as compared to Rs. 253.4 crores in the corresponding period of the previous year.
- Crop protection sales up by 30.2% to Rs. 171.7 crores as compared to Rs. 138.8 crores in the corresponding period of the previous year.
- EBIDTA was lower by 12.3% to Rs. 91.1 crores as compared to Rs. 103.8 crores in the corresponding period of the previous year.



HIKAL LTD





• Net Profit was reduced by 58.7% at Rs. 21 crores as compared to Rs. 50.7 crores in the corresponding period of the previous year. In the half year of the previous year there was an exceptional income of Rs. 25.7 crores (net of taxes) from the sale of shares pertaining to the ESOP trust.

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said, "We have recorded our highest ever quarterly revenues which are up 20% to Rs. 242.9 crores. Our EBITDA is lower due to a reduction in selling prices however larger market share for our products have been realized by our customers due to competitive prices given by us. The forecast for the remaining part of the year is positive in terms of revenues and we expect our margins to stabilize at these levels for the remaining part of the financial year. The overall business environment is positive for both divisions and we expect our growth to continue in the future quarters."

About Hikal:

Hikal is a reliable long-term partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates, manufactured using stringent global quality standards, for its global customers. Hikal's advanced manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad (Maharashtra). Hikal's R&D facilities are located at Pune. The Pharmaceutical manufacturing facilities are situated in Jigani (Bangalore) and Panoli (Gujarat).

Safe harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

Hikal Ltd. – **Anish Swadi** @+91-22-30973100, Email – <u>anish swadi@hikal.com</u>
Strategic Growth Advisors Pvt. — Payal Dave@+912261146679 – <u>dpayal@sgapl.net</u>

Page 2 of 2

HIKAL LTD

CIM: L24290MH1988PTC048028